BIND Therapeutics (BIND) Tops Q3 EPS by 3c; Sees Milestone Payment from AstraZeneca in Q4

BIND Therapeutics (NASDAQ: BIND) reported Q3 EPS of ($0.49), $0.03 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.14 million.

The company also said : We expect to earn a $4.0 million milestone from AstraZeneca (NYSE: AZN) during the fourth quarter of 2015 for the first patient in a phase 1 trial for Accurin AZD2811. We only include milestones in our cash guidance once they are achieved.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Bragg Gaming Group Inc. (BRAG) Tops Q2 EPS by 2c
• Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance